Clinical trial
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France
NCT03858478 is registered in ClinicalTrials.gov with Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France
- Lead sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- November 18, 2019
- Completion date
- December 31, 2021
- Enrollment
- 110 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.